BCGP STUDY GUIDE TEST

WBC (leukocytes) - ANSWER 3.2-11.3

RBC (erythrocytes) - ANSWER M: >4.2
F: >3.5

Hemoglobin - ANSWER Male: 14-18
Female: 12-16

Hematocrit - ANSWER M: >39%
F: >33%

MCV (mean corpuscular volume) - ANSWER 76-100

Carvedilol P450 Substrate - ANSWER 2D6

Metoprolol P450 Substrate - ANSWER 2D6

Codeine P450 Substrate - ANSWER 2D6

PPIs P450 Substrate - ANSWER 2C19

Clopidogrel P450 Substrate - ANSWER 2C19

Citalopram P450 Substrate - ANSWER 2C19

Benzos (alp/dia/mida/triaz) P450 Substrate - ANSWER 3A4

2D6 inhibitors - ANSWER +++ bupropion, fluoxetine, paroxetine
++ duloxetine

2C19 inhibitors - ANSWER PPIs

, fluoxetine/fluvoxamine

2D6 inducers - ANSWER none - 2D6 considered non-inducible enzyme

Antipsychotic P450 substrate - ANSWER mostly 2D6

metformin causes what deficiency - ANSWER B12

SGLT2 inhibitor pearls (flozins) - ANSWER renally dosed, cardiac benefits
(empaglifloz)

DPP4 inhibitor pearls (gliptans) - ANSWER inc CHF hospitalization,
pancreatitis, renal limits, joint pain

GLP1 agonists pearls (natides) - ANSWER injectable, cardiac outcomes, more
effective than DPP4s

MMSE - ANSWER 24-30 normal
18-23 mild
10-17 mod
<10 sev

MoCA - ANSWER more effective than MMSE, 20+ languages
26-30 normal
<26 MCI or dementia

SBT and ADAS-Cog - ANSWER cognitive assessments

GDS - ANSWER Geriatric Depression Scale

PHQ - ANSWER PHQ2 or PHQ9, depression questionnarie

Cornell Scale - ANSWER for depression in Dementia

Hamilton - ANSWER depression scale, need training to perform

TMT - ANSWER trail making test - cognitive function